RUA vs. POLX, MHC, SUN, DEMG, BELL, IHC, CNSL, ROQ, GDR, and GENF
Should you be buying RUA Life Sciences stock or one of its competitors? The main competitors of RUA Life Sciences include Polarean Imaging (POLX), MyHealthChecked (MHC), Surgical Innovations Group (SUN), Deltex Medical Group (DEMG), Belluscura (BELL), Inspiration Healthcare Group (IHC), Cambridge Nutritional Sciences (CNSL), Roquefort Therapeutics (ROQ), genedrive (GDR), and Genflow Biosciences (GENF). These companies are all part of the "medical" sector.
RUA Life Sciences (LON:RUA) and Polarean Imaging (LON:POLX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, community ranking, profitability, valuation and dividends.
RUA Life Sciences has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Polarean Imaging has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500.
RUA Life Sciences has higher revenue and earnings than Polarean Imaging. RUA Life Sciences is trading at a lower price-to-earnings ratio than Polarean Imaging, indicating that it is currently the more affordable of the two stocks.
Polarean Imaging has a net margin of 0.00% compared to RUA Life Sciences' net margin of -100.05%. RUA Life Sciences' return on equity of -40.56% beat Polarean Imaging's return on equity.
Polarean Imaging received 23 more outperform votes than RUA Life Sciences when rated by MarketBeat users. Likewise, 67.65% of users gave Polarean Imaging an outperform vote while only 0.00% of users gave RUA Life Sciences an outperform vote.
In the previous week, RUA Life Sciences had 1 more articles in the media than Polarean Imaging. MarketBeat recorded 1 mentions for RUA Life Sciences and 0 mentions for Polarean Imaging. RUA Life Sciences' average media sentiment score of 0.00 equaled Polarean Imaging'saverage media sentiment score.
20.7% of RUA Life Sciences shares are owned by institutional investors. Comparatively, 23.4% of Polarean Imaging shares are owned by institutional investors. 20.9% of RUA Life Sciences shares are owned by insiders. Comparatively, 28.0% of Polarean Imaging shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Polarean Imaging beats RUA Life Sciences on 8 of the 14 factors compared between the two stocks.
Get RUA Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RUA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RUA Life Sciences Competitors List
Related Companies and Tools
